Last reviewed · How we verify
crisaborole ointment
Crisaborole inhibits phosphodiesterase 4 (PDE4), leading to increased levels of cyclic AMP (cAMP) which has anti-inflammatory effects.
Crisaborole inhibits phosphodiesterase 4 (PDE4), leading to increased levels of cyclic AMP (cAMP) which has anti-inflammatory effects. Used for Atopic dermatitis in patients 2 years of age and older.
At a glance
| Generic name | crisaborole ointment |
|---|---|
| Also known as | Eucrisa |
| Sponsor | Pfizer |
| Drug class | PDE4 inhibitor |
| Target | PDE4 |
| Modality | Small molecule |
| Therapeutic area | Dermatology |
| Phase | Phase 3 |
Mechanism of action
By inhibiting PDE4, crisaborole prevents the breakdown of cAMP, resulting in reduced inflammation and immune response in the skin. This makes it effective for treating atopic dermatitis.
Approved indications
- Atopic dermatitis in patients 2 years of age and older
Common side effects
- Application site pain
- Upper respiratory tract infection
Key clinical trials
- Comparative Evaluation of the Safety and Effectiveness of Crisaborole Ointment (2%) Versus Tacrolimus Ointment (0.1%) for the Topical Treatment of Atopic Dermatitis (PHASE4)
- Comparative Study of Crisaborole vs. Tacrolimus in Atopic Dermatitis (PHASE4)
- Crisaborole 2% Versus Tacrolimus 0.1% in Children With Mild to Moderate Atopic Dermatitis (PHASE3)
- Microneedling Combined With Topical Crisaborole 2 % Ointment in Treatment of Vitiligo. (NA)
- Skin bioMARkers for Atopic Eczema Therapy Evaluation (PHASE2)
- Eucrisa for Atopic Dermatitis (PHASE1)
- Improvement In Scratch Behavior And Sleep In Patients With Atopic Dermatitis (PHASE4)
- Topical Crisaborole in Patients with Alopecia Areata (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- crisaborole ointment CI brief — competitive landscape report
- crisaborole ointment updates RSS · CI watch RSS
- Pfizer portfolio CI